Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKAR | P32238 | 12/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TEK | Q02763 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.38 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.38 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5093419 | 0.92 | CCKAR (0.51) | CCKARMAPTKDM4EMEN1ALDH1A1 | |
| SCHEMBL5093279 | 0.91 | CCKAR (0.51) | CCKARMAPTKDM4EMEN1ALDH1A1 | |
| SCHEMBL5093258 | 0.89 | CCKAR (0.40) | CCKARMAPTKDM4EMEN1ALDH1A1 | |
| SCHEMBL5093271 | 0.88 | CCKAR (0.49) | CCKARMAPTKDM4EMEN1ALDH1A1 | |
| SCHEMBL5093239 | 0.84 | MAPT (0.42) | CCKARMAPTKDM4EMEN1ALDH1A1 | |
| SCHEMBL5094344 | 0.74 | CCKAR (0.46) | CCKARMAPTKDM4EMEN1ALDH1A1 | |
| SCHEMBL5091262 | 0.73 | TEK (0.40) | MAPTKDM4EMEN1ALDH1A1CYP1A2 | |
| SCHEMBL5091286 | 0.72 | MAPT (0.42) | MAPTKDM4EMEN1ALDH1A1CYP1A2 | |
| SCHEMBL5091295 | 0.72 | MAPT (0.42) | MAPTKDM4EMEN1ALDH1A1CYP1A2 | |
| SCHEMBL5098904 | 0.72 | MAPT (0.42) | MAPTKDM4EMEN1ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456208-B2 | CCK-1 receptor modulators | JANSSEN PHARMACEUTICA N.V. (BG) | 2008-11-25 | — | — | US | claimed |
| US-20070249698-A1 | CCK-1 Receptor Modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-25 | — | — | US | claimed |
| US-7250434-B2 | CCK-1 receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-31 | — | — | US | claimed |
| US-20050197377-A1 | CCK-1 receptor modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-09-08 | — | — | US | claimed |
| WO-2005063716-A1 | IMIDAZOLES AND THEIR USE CCK-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-07-14 | — | — | WO | claimed |
| US-7456208-B2 | CCK-1 receptor modulators | JANSSEN PHARMACEUTICA N.V. (BG) | 2008-11-25 | — | — | US | disclosed |
| US-7456208-B2 | CCK-1 receptor modulators | JANSSEN PHARMACEUTICA N.V. (BG) | 2008-11-25 | — | — | US | disclosed |
| US-7456208-B2 | CCK-1 receptor modulators | JANSSEN PHARMACEUTICA N.V. (BG) | 2008-11-25 | — | — | US | disclosed |
| US-20070249698-A1 | CCK-1 Receptor Modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-25 | — | — | US | disclosed |
| US-20070249698-A1 | CCK-1 Receptor Modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-25 | — | — | US | disclosed |
| US-20070249698-A1 | CCK-1 Receptor Modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-25 | — | — | US | disclosed |
| US-7250434-B2 | CCK-1 receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-31 | — | — | US | disclosed |
| US-7250434-B2 | CCK-1 receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-31 | — | — | US | disclosed |
| US-7250434-B2 | CCK-1 receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-31 | — | — | US | disclosed |
| US-20050197377-A1 | CCK-1 receptor modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-09-08 | — | — | US | disclosed |
| WO-2005063716-A1 | IMIDAZOLES AND THEIR USE CCK-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197377-A1 | CCK-1 receptor modulators | CCKAR, CCKBR, GIPR | CCKAR 1/4885MAPT 4128/4885KDM4E 4205/4885 |
| US-20070249698-A1 | CCK-1 Receptor Modulators | CCKAR, CCKBR, GIPR | CCKAR 1/4885MAPT 4128/4885KDM4E 4205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.